Eli Lilly and Company said it will present new data spanning four of its obesity-related therapies — Zepbound, Foundayo, EloraTZP and retatrutide — at the ObesityWeek 2026 conference, according to the announcement. The company framed the upcoming presentations around evaluating obesity treatment through measures that go, as the release put it, "beyond the scale."

Key takeaways

  • Eli Lilly announced it will present new data on four obesity-related therapies at the ObesityWeek 2026 conference.
  • The lineup spans Zepbound, Foundayo, EloraTZP and retatrutide, covering both approved and investigational treatments.
  • Lilly says the data will frame obesity care around measures beyond body weight alone, described as moving treatment evaluation "beyond the scale."
  • The company's announcement did not include specific trial results, presentation dates or conference locations.

Key details

What is in Lilly's obesity portfolio

Zepbound is Lilly's branded version of tirzepatide, a drug that activates both the GLP-1 and GIP hormone receptors and is approved in the United States for chronic weight management. It is already on the market and has been one of the central products in Lilly's push into the obesity drug category, alongside competitors such as Novo Nordisk's Wegovy.

Retatrutide is an investigational drug further along Lilly's pipeline, designed to act on three separate hormone receptors — GLP-1, GIP and glucagon — rather than two. It has been studied in clinical trials as a potential next-generation treatment for obesity and related conditions, though it has not received regulatory approval. The release did not provide detail on the stage of testing for Foundayo or EloraTZP, the other two names included in the announcement, beyond listing them alongside Zepbound and retatrutide as part of the data being presented.

Why the industry is looking past body weight

The phrase Lilly used to describe its presentations — moving obesity care "beyond the scale" — reflects a broader trend among drugmakers and researchers in the obesity field. Body weight alone has long been the primary metric used to judge whether a treatment works, but researchers and clinicians have increasingly pushed to track other outcomes, such as changes in blood sugar control, cardiovascular risk markers, body composition, or quality of life, as a fuller picture of a drug's effect on a patient's health.

For patients and investors watching the obesity drug market, the shift in emphasis matters because it can affect how new therapies are judged, priced and positioned against competitors. A drug that shows strong effects on metabolic or cardiovascular markers, not just pounds lost, could carry a different value proposition for insurers and health systems that pay for these treatments over the long term.

Background on ObesityWeek and what happens next

ObesityWeek is an annual conference where researchers, clinicians and pharmaceutical companies present clinical trial results and other scientific findings related to obesity treatment and related metabolic conditions. It has become one of the key industry gatherings where companies such as Lilly and its rivals disclose new trial data on weight-management drugs, often drawing significant attention from investors and medical professionals tracking the fast-growing obesity drug market.

The release reviewed for this story did not specify the dates or location of ObesityWeek 2026, nor did it detail the specific studies, patient numbers or results that Lilly plans to disclose. Those specifics, including any new efficacy or safety data on Zepbound, Foundayo, EloraTZP or retatrutide, would typically be released at or around the time of the conference presentations themselves.

Frequently asked questions

What is ObesityWeek?

ObesityWeek is an annual conference focused on obesity research and treatment, where pharmaceutical companies and researchers present new clinical data on weight-management therapies. It is widely used by drugmakers like Eli Lilly to disclose trial results tied to their obesity drug pipelines.

What is the difference between Zepbound and retatrutide?

Zepbound is Lilly's already-approved tirzepatide product for chronic weight management, acting on two hormone receptors (GLP-1 and GIP). Retatrutide is an investigational drug still being studied that targets three hormone receptors (GLP-1, GIP and glucagon) and has not received regulatory approval.

When will the new data be released?

Lilly's announcement did not specify the date of the ObesityWeek 2026 conference or when the new data on these therapies would be formally presented. Such details are typically disclosed closer to or during the conference itself.